Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. [PDF]
Borbon LC +11 more
europepmc +1 more source
The South Australian <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival. [PDF]
Altus LM +11 more
europepmc +1 more source
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. [PDF]
Severi S +21 more
europepmc +1 more source
Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center. [PDF]
Mathew D +7 more
europepmc +1 more source
Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study. [PDF]
von Hessert-Vaudoncourt C +10 more
europepmc +1 more source
Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids. [PDF]
Reuvers TGA +6 more
europepmc +1 more source
Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors. [PDF]
Alayli A +9 more
europepmc +1 more source
The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience. [PDF]
Piscopo L +10 more
europepmc +1 more source
Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience. [PDF]
Sukrithan V +19 more
europepmc +1 more source

